CA2692501A1 - Variantes hyperactives de la proteine transposase du systeme de transposon sleeping beauty - Google Patents

Variantes hyperactives de la proteine transposase du systeme de transposon sleeping beauty Download PDF

Info

Publication number: CA2692501A1
Authority: CA; Canada
Prior art keywords: cndot; variant; nucleic acid; transposon; mutations
Prior art date: 2007-07-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA 2692501

Other languages

English (en)

Other versions

CA2692501C (fr

Inventor

Zsuzsanna Izsvak

Zoltan Ivics

Lajos Mates

Carmen-Anisia Judis

Andrea Katzer

Namitha Manoj

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-04

Filing date

2008-06-30

Publication date

2009-01-08

2007-08-17 Priority claimed from EP07016202A external-priority patent/EP2025748A1/fr

2008-06-30 Application filed by Individual filed Critical Individual

2009-01-08 Publication of CA2692501A1 publication Critical patent/CA2692501A1/fr

2017-10-10 Application granted granted Critical

2017-10-10 Publication of CA2692501C publication Critical patent/CA2692501C/fr

Status Active legal-status Critical Current

2028-06-30 Anticipated expiration legal-status Critical

Links

108010020764 Transposases Proteins 0.000 title claims abstract description 225
102000008579 Transposases Human genes 0.000 title claims abstract description 220
240000007019 Oxalis corniculata Species 0.000 title abstract description 137
108090000623 proteins and genes Proteins 0.000 claims abstract description 224
150000007523 nucleic acids Chemical class 0.000 claims abstract description 150
102000039446 nucleic acids Human genes 0.000 claims abstract description 100
108020004707 nucleic acids Proteins 0.000 claims abstract description 100
108020004414 DNA Proteins 0.000 claims abstract description 81
238000012546 transfer Methods 0.000 claims abstract description 79
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 59
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
238000000338 in vitro Methods 0.000 claims abstract description 8
102100038185 Keratin, type I cuticular Ha3-I Human genes 0.000 claims description 208
101710199510 Keratin, type I cuticular Ha3-I Proteins 0.000 claims description 208
102200068713 rs281865218 Human genes 0.000 claims description 205
210000004027 cell Anatomy 0.000 claims description 185
230000035772 mutation Effects 0.000 claims description 132
108090000765 processed proteins & peptides Proteins 0.000 claims description 91
102000004196 processed proteins & peptides Human genes 0.000 claims description 90
229920001184 polypeptide Polymers 0.000 claims description 89
230000014509 gene expression Effects 0.000 claims description 56
239000005090 green fluorescent protein Substances 0.000 claims description 56
238000000034 method Methods 0.000 claims description 53
108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 50
102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 50
102000004169 proteins and genes Human genes 0.000 claims description 48
150000001413 amino acids Chemical class 0.000 claims description 45
102200153443 rs768834663 Human genes 0.000 claims description 42
239000013612 plasmid Substances 0.000 claims description 27
241000282414 Homo sapiens Species 0.000 claims description 24
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 19
230000001225 therapeutic effect Effects 0.000 claims description 18
230000001105 regulatory effect Effects 0.000 claims description 17
241001465754 Metazoa Species 0.000 claims description 16
108700026244 Open Reading Frames Proteins 0.000 claims description 16
102220507306 Rab11 family-interacting protein 1_K13A_mutation Human genes 0.000 claims description 15
239000003550 marker Substances 0.000 claims description 15
239000013603 viral vector Substances 0.000 claims description 15
241000251468 Actinopterygii Species 0.000 claims description 11
239000003623 enhancer Substances 0.000 claims description 11
239000002773 nucleotide Substances 0.000 claims description 10
125000003729 nucleotide group Chemical group 0.000 claims description 10
241000124008 Mammalia Species 0.000 claims description 9
238000004520 electroporation Methods 0.000 claims description 9
231100000350 mutagenesis Toxicity 0.000 claims description 9
239000003981 vehicle Substances 0.000 claims description 8
239000002671 adjuvant Substances 0.000 claims description 7
239000003153 chemical reaction reagent Substances 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
150000002632 lipids Chemical class 0.000 claims description 7
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 6
108060001084 Luciferase Proteins 0.000 claims description 6
239000005089 Luciferase Substances 0.000 claims description 6
108091092566 Extrachromosomal DNA Proteins 0.000 claims description 5
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
102000013275 Somatomedins Human genes 0.000 claims description 5
238000000520 microinjection Methods 0.000 claims description 5
230000003584 silencer Effects 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
102000018997 Growth Hormone Human genes 0.000 claims description 3
108010051696 Growth Hormone Proteins 0.000 claims description 3
210000004102 animal cell Anatomy 0.000 claims description 3
239000000122 growth hormone Substances 0.000 claims description 3
230000002103 transcriptional effect Effects 0.000 claims description 3
238000002255 vaccination Methods 0.000 claims description 3
101150066555 lacZ gene Proteins 0.000 claims description 2
239000002245 particle Substances 0.000 claims description 2
102220199585 rs1057521790 Human genes 0.000 claims 196
125000003275 alpha amino acid group Chemical group 0.000 claims 4
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 1
108700039855 mouse a Proteins 0.000 claims 1
238000001727 in vivo Methods 0.000 abstract description 19
238000000581 reactive spray deposition Methods 0.000 abstract description 17
101150041393 rsd gene Proteins 0.000 abstract description 17
238000001415 gene therapy Methods 0.000 abstract description 13
238000002743 insertional mutagenesis Methods 0.000 abstract description 6
238000013507 mapping Methods 0.000 abstract description 3
238000010230 functional analysis Methods 0.000 abstract description 2
238000012106 screening analysis Methods 0.000 abstract description 2
102220211613 rs3769823 Human genes 0.000 description 219
230000000694 effects Effects 0.000 description 46
235000018102 proteins Nutrition 0.000 description 45
210000000130 stem cell Anatomy 0.000 description 35
230000017105 transposition Effects 0.000 description 32
239000012634 fragment Substances 0.000 description 31
108091026890 Coding region Proteins 0.000 description 30
239000013598 vector Substances 0.000 description 30
238000003780 insertion Methods 0.000 description 25
230000037431 insertion Effects 0.000 description 25
102100022641 Coagulation factor IX Human genes 0.000 description 23
108010076282 Factor IX Proteins 0.000 description 23
229960004222 factor ix Drugs 0.000 description 23
239000000203 mixture Substances 0.000 description 22
235000001014 amino acid Nutrition 0.000 description 19
210000003013 erythroid precursor cell Anatomy 0.000 description 19
238000001890 transfection Methods 0.000 description 17
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 13
230000003612 virological effect Effects 0.000 description 13
230000009261 transgenic effect Effects 0.000 description 12
-1 GDP-DI Proteins 0.000 description 11
206010028980 Neoplasm Diseases 0.000 description 11
238000010835 comparative analysis Methods 0.000 description 11
230000001404 mediated effect Effects 0.000 description 11
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 10
101100220044 Homo sapiens CD34 gene Proteins 0.000 description 10
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 10
241000700605 Viruses Species 0.000 description 10
210000003995 blood forming stem cell Anatomy 0.000 description 10
210000003098 myoblast Anatomy 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
239000000047 product Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
238000011144 upstream manufacturing Methods 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
108020004459 Small interfering RNA Proteins 0.000 description 8
238000010367 cloning Methods 0.000 description 8
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
230000000925 erythroid effect Effects 0.000 description 8
230000010354 integration Effects 0.000 description 8
238000011282 treatment Methods 0.000 description 8
238000013459 approach Methods 0.000 description 7
230000003197 catalytic effect Effects 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
210000003205 muscle Anatomy 0.000 description 7
230000008569 process Effects 0.000 description 7
238000012163 sequencing technique Methods 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
201000009030 Carcinoma Diseases 0.000 description 6
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
101100088247 Picea mariana RPL13A gene Proteins 0.000 description 6
108091081062 Repeated sequence (DNA) Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000000427 antigen Substances 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
239000006285 cell suspension Substances 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
230000002068 genetic effect Effects 0.000 description 6
210000003958 hematopoietic stem cell Anatomy 0.000 description 6
210000003494 hepatocyte Anatomy 0.000 description 6
208000013403 hyperactivity Diseases 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
210000001665 muscle stem cell Anatomy 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
201000011510 cancer Diseases 0.000 description 5
238000009643 clonogenic assay Methods 0.000 description 5
231100000096 clonogenic assay Toxicity 0.000 description 5
238000012761 co-transfection Methods 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
210000003714 granulocyte Anatomy 0.000 description 5
230000012010 growth Effects 0.000 description 5
238000002955 isolation Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
238000002703 mutagenesis Methods 0.000 description 5
235000002639 sodium chloride Nutrition 0.000 description 5
239000000243 solution Substances 0.000 description 5
241000894007 species Species 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
238000013519 translation Methods 0.000 description 5
239000002753 trypsin inhibitor Substances 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
102100029855 Caspase-3 Human genes 0.000 description 4
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
241000276569 Oryzias latipes Species 0.000 description 4
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
108700019146 Transgenes Proteins 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
240000008042 Zea mays Species 0.000 description 4
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 4
235000002017 Zea mays subsp mays Nutrition 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
239000002270 dispersing agent Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
235000009973 maize Nutrition 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000006798 recombination Effects 0.000 description 4
238000005215 recombination Methods 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
125000006850 spacer group Chemical group 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
108020005544 Antisense RNA Proteins 0.000 description 3
102000004091 Caspase-8 Human genes 0.000 description 3
108090000538 Caspase-8 Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
201000003883 Cystic fibrosis Diseases 0.000 description 3
230000004568 DNA-binding Effects 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000001398 Granzyme Human genes 0.000 description 3
108060005986 Granzyme Proteins 0.000 description 3
101000823435 Homo sapiens Coagulation factor IX Proteins 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
241000270942 Rana pipiens Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000027455 binding Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000002759 chromosomal effect Effects 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
230000002950 deficient Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
235000013601 eggs Nutrition 0.000 description 3
210000001671 embryonic stem cell Anatomy 0.000 description 3
210000004700 fetal blood Anatomy 0.000 description 3
102000034287 fluorescent proteins Human genes 0.000 description 3
108091006047 fluorescent proteins Proteins 0.000 description 3
230000006870 function Effects 0.000 description 3
230000009368 gene silencing by RNA Effects 0.000 description 3
210000004602 germ cell Anatomy 0.000 description 3
229940052349 human coagulation factor ix Drugs 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
201000006747 infectious mononucleosis Diseases 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000003593 megakaryocyte Anatomy 0.000 description 3
230000000869 mutational effect Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
235000019271 petrolatum Nutrition 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
108091005957 yellow fluorescent proteins Proteins 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
102000055025 Adenosine deaminases Human genes 0.000 description 2
108010031426 Anemonia sulcata FP595 protein Proteins 0.000 description 2
240000001436 Antirrhinum majus Species 0.000 description 2
241000271566 Aves Species 0.000 description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
208000011691 Burkitt lymphomas Diseases 0.000 description 2
241000283707 Capra Species 0.000 description 2
108090000397 Caspase 3 Proteins 0.000 description 2
102100035904 Caspase-1 Human genes 0.000 description 2
108090000426 Caspase-1 Proteins 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 2
101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 2
101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 2
101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102100020873 Interleukin-2 Human genes 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
241001494479 Pecora Species 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 2
108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 2
102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 2
102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000003796 beauty Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
108091005948 blue fluorescent proteins Proteins 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
238000009709 capacitor discharge sintering Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
108010082025 cyan fluorescent protein Proteins 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
108010045262 enhanced cyan fluorescent protein Proteins 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000030279 gene silencing Effects 0.000 description 2
238000012252 genetic analysis Methods 0.000 description 2
230000009395 genetic defect Effects 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
210000000777 hematopoietic system Anatomy 0.000 description 2
230000006872 improvement Effects 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
208000007538 neurilemmoma Diseases 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
238000012753 partial hepatectomy Methods 0.000 description 2
244000052769 pathogen Species 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
229920002477 rna polymer Polymers 0.000 description 2
206010039667 schwannoma Diseases 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000010473 stable expression Effects 0.000 description 2
238000003153 stable transfection Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 description 1
VBMOHECZZWVLFJ-GXTUVTBFSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]hexanoyl]amino]propanoyl]amino]hexan Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCCN VBMOHECZZWVLFJ-GXTUVTBFSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
101150072531 10 gene Proteins 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
102000009346 Adenosine receptors Human genes 0.000 description 1
108050000203 Adenosine receptors Proteins 0.000 description 1
208000010370 Adenoviridae Infections Diseases 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
240000000489 Agave utahensis Species 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000007887 Alphavirus Infections Diseases 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
208000009828 Arbovirus Infections Diseases 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
201000001178 Bacterial Pneumonia Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
208000024956 Borna Disease Diseases 0.000 description 1
208000003508 Botulism Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010006417 Bronchial carcinoma Diseases 0.000 description 1
208000008371 Bunyaviridae Infections Diseases 0.000 description 1
208000026429 Bunyaviridae infectious disease Diseases 0.000 description 1
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
101150029409 CFTR gene Proteins 0.000 description 1
241000244203 Caenorhabditis elegans Species 0.000 description 1
101100004280 Caenorhabditis elegans best-2 gene Proteins 0.000 description 1
101100167280 Caenorhabditis elegans cin-4 gene Proteins 0.000 description 1
101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 1
102100024436 Caldesmon Human genes 0.000 description 1
208000006339 Caliciviridae Infections Diseases 0.000 description 1
208000023722 Caliciviridae infectious disease Diseases 0.000 description 1
102000007590 Calpain Human genes 0.000 description 1
108010032088 Calpain Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
108090000425 Caspase 6 Proteins 0.000 description 1
102000004018 Caspase 6 Human genes 0.000 description 1
108090000567 Caspase 7 Proteins 0.000 description 1
108090000572 Caspase-10 Proteins 0.000 description 1
102100026549 Caspase-10 Human genes 0.000 description 1
102000004046 Caspase-2 Human genes 0.000 description 1
108090000552 Caspase-2 Proteins 0.000 description 1
102100025597 Caspase-4 Human genes 0.000 description 1
101710090338 Caspase-4 Proteins 0.000 description 1
102100038916 Caspase-5 Human genes 0.000 description 1
101710090333 Caspase-5 Proteins 0.000 description 1
102100038902 Caspase-7 Human genes 0.000 description 1
108090000566 Caspase-9 Proteins 0.000 description 1
102100026550 Caspase-9 Human genes 0.000 description 1
102000011727 Caspases Human genes 0.000 description 1
108010076667 Caspases Proteins 0.000 description 1
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
101710082464 Cis-aconitate decarboxylase Proteins 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001528 Coronaviridae Infections Diseases 0.000 description 1
208000002077 Coxsackievirus Infections Diseases 0.000 description 1
241000238424 Crustacea Species 0.000 description 1
102100037912 Cyclin-dependent kinase 11A Human genes 0.000 description 1
102100030497 Cytochrome c Human genes 0.000 description 1
108010075031 Cytochromes c Proteins 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
208000004449 DNA Virus Infections Diseases 0.000 description 1
102100038026 DNA fragmentation factor subunit alpha Human genes 0.000 description 1
101710182628 DNA fragmentation factor subunit alpha Proteins 0.000 description 1
101710147299 DNA fragmentation factor subunit beta Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102100028559 Death domain-associated protein 6 Human genes 0.000 description 1
101710091772 Death domain-associated protein 6 Proteins 0.000 description 1
102100038713 Death domain-containing protein CRADD Human genes 0.000 description 1
241000238557 Decapoda Species 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
208000001490 Dengue Diseases 0.000 description 1
206010012310 Dengue fever Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000002699 Digestive System Neoplasms Diseases 0.000 description 1
241000255925 Diptera Species 0.000 description 1
208000035240 Disease Resistance Diseases 0.000 description 1
108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
208000007985 Erythema Infectiosum Diseases 0.000 description 1
102100031690 Erythroid transcription factor Human genes 0.000 description 1
101710100588 Erythroid transcription factor Proteins 0.000 description 1
102100026693 FAS-associated death domain protein Human genes 0.000 description 1
108010023321 Factor VII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010016952 Food poisoning Diseases 0.000 description 1
208000019331 Foodborne disease Diseases 0.000 description 1
102100029115 Fumarylacetoacetase Human genes 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108090001064 Gelsolin Proteins 0.000 description 1
102000004878 Gelsolin Human genes 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
102100033417 Glucocorticoid receptor Human genes 0.000 description 1
102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
102000004547 Glucosylceramidase Human genes 0.000 description 1
108010017544 Glucosylceramidase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100035716 Glycophorin-A Human genes 0.000 description 1
108091005250 Glycophorins Proteins 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
241001123589 Gorilla papillomavirus Species 0.000 description 1
206010061192 Haemorrhagic fever Diseases 0.000 description 1
208000008913 Hantavirus Infections Diseases 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
206010063491 Herpes zoster oticus Diseases 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 description 1
108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 description 1
101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
101000738403 Homo sapiens Cyclin-dependent kinase 11A Proteins 0.000 description 1
101000957914 Homo sapiens Death domain-containing protein CRADD Proteins 0.000 description 1
101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
208000002979 Influenza in Birds Diseases 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
208000005016 Intestinal Neoplasms Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
108010021101 Lamin Type B Proteins 0.000 description 1
206010023927 Lassa fever Diseases 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010024641 Listeriosis Diseases 0.000 description 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010059282 Metastases to central nervous system Diseases 0.000 description 1
102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
101710164423 Mitogen-activated protein kinase kinase kinase 1 Proteins 0.000 description 1
241000237852 Mollusca Species 0.000 description 1
206010048723 Multiple-drug resistance Diseases 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
101100381649 Mus musculus Bik gene Proteins 0.000 description 1
101100390735 Mus musculus Figla gene Proteins 0.000 description 1
101100447665 Mus musculus Gas2 gene Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 1
241000237502 Ostreidae Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
206010033971 Paratyphoid fever Diseases 0.000 description 1
241000237503 Pectinidae Species 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
102000004503 Perforin Human genes 0.000 description 1
108010056995 Perforin Proteins 0.000 description 1
KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
206010034811 Pharyngeal cancer Diseases 0.000 description 1
108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
201000000239 Phlebotomus fever Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
208000001676 Polyomavirus Infections Diseases 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
102000015499 Presenilins Human genes 0.000 description 1
108010050254 Presenilins Proteins 0.000 description 1
101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
101710145525 Probable cinnamyl alcohol dehydrogenase Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
208000009341 RNA Virus Infections Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
101710124357 Retinoblastoma-associated protein Proteins 0.000 description 1
208000000705 Rift Valley Fever Diseases 0.000 description 1
206010039587 Scarlet Fever Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
101710148167 Serine/threonine-protein kinase PAK 2 Proteins 0.000 description 1
102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 description 1
101100174184 Serratia marcescens fosA gene Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000011942 Slow Virus disease Diseases 0.000 description 1
102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102100023132 Transcription factor Jun Human genes 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
108060008539 Transglutaminase Proteins 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
208000004062 Tumor Virus Infections Diseases 0.000 description 1
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 1
208000037386 Typhoid Diseases 0.000 description 1
108060008724 Tyrosinase Proteins 0.000 description 1
108010058532 UTP-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 1
102000006321 UTP-hexose-1-phosphate uridylyltransferase Human genes 0.000 description 1
206010046431 Urethral cancer Diseases 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
201000006449 West Nile encephalitis Diseases 0.000 description 1
206010057293 West Nile viral infection Diseases 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
208000003152 Yellow Fever Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
229940124532 absorption promoter Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
208000011589 adenoviridae infectious disease Diseases 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
201000007538 anal carcinoma Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
208000034615 apoptosis-related disease Diseases 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
229910002056 binary alloy Inorganic materials 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
101150055276 ced-3 gene Proteins 0.000 description 1
101150039936 ced-9 gene Proteins 0.000 description 1
230000003915 cell function Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229940106189 ceramide Drugs 0.000 description 1
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000000306 component Substances 0.000 description 1
238000004624 confocal microscopy Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
101150044687 crm gene Proteins 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
208000025729 dengue disease Diseases 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
201000010582 ecthyma Diseases 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
210000000267 erythroid cell Anatomy 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
108010006620 fodrin Proteins 0.000 description 1
101150078861 fos gene Proteins 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
239000013505 freshwater Substances 0.000 description 1
108010022687 fumarylacetoacetase Proteins 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
201000011349 geniculate herpes zoster Diseases 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
208000029629 hantavirus infectious disease Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
241000238565 lobster Species 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000000998 lymphohematopoietic effect Effects 0.000 description 1
108010068904 lysyl-arginyl-alanyl-lysyl-alanyl-lysyl-threonyl-threonyl-lysyl-lysyl-arginine Proteins 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
229960003730 methylcellulose (4000 cps) Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
229940042472 mineral oil Drugs 0.000 description 1
230000001483 mobilizing effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000008588 molluscum contagiosum Diseases 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
231100000707 mutagenic chemical Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
238000013188 needle biopsy Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
235000020636 oyster Nutrition 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229930192851 perforin Natural products 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
201000002511 pituitary cancer Diseases 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000001566 pro-viral effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
210000003314 quadriceps muscle Anatomy 0.000 description 1
208000020615 rectal carcinoma Diseases 0.000 description 1
229940100618 rectal suppository Drugs 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
108010054624 red fluorescent protein Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
235000020637 scallop Nutrition 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
208000014680 small intestine neoplasm Diseases 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
210000001988 somatic stem cell Anatomy 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
208000008732 thymoma Diseases 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000009466 transformation Effects 0.000 description 1
102000003601 transglutaminase Human genes 0.000 description 1
238000001926 trapping method Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
201000004364 trench fever Diseases 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
201000008297 typhoid fever Diseases 0.000 description 1
206010061393 typhus Diseases 0.000 description 1
201000000360 urethra cancer Diseases 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Fodder In General (AREA)

CA2692501A 2007-07-04 2008-06-30 Variantes hyperactives de la proteine transposase du systeme de transposon sleeping beauty Active CA2692501C (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP07013109		2007-07-04
EP07013109.9		2007-07-04
EP07016202.9		2007-08-17
EP07016202A EP2025748A1 (fr)	2007-08-17	2007-08-17	Variantes hyperactives de protéine transposase du système de transposon sleeping beauty
PCT/EP2008/005342 WO2009003671A2 (fr)	2007-07-04	2008-06-30	Variantes hyperactives de la protéine transposase du système de transposon sleeping beauty

Publications (2)

Publication Number	Publication Date
CA2692501A1 true CA2692501A1 (fr)	2009-01-08
CA2692501C CA2692501C (fr)	2017-10-10

Family

ID=39791160

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2692501A Active CA2692501C (fr)	2007-07-04	2008-06-30	Variantes hyperactives de la proteine transposase du systeme de transposon sleeping beauty

Country Status (6)

Country	Link
US (4)	US9228180B2 (fr)
EP (1)	EP2160461B1 (fr)
JP (1)	JP5726522B2 (fr)
AU (1)	AU2008271523B2 (fr)
CA (1)	CA2692501C (fr)
WO (1)	WO2009003671A2 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5726522B2 (ja) *	2007-07-04	2015-06-03	マックス−デルブリュック−ツェントルムフューアモレキュラーレメディツィン	トランスポゾンシステム−スリーピングビューティーのトランスポザーゼタンパク質の機能亢進性バリアント
WO2010083842A2 (fr)	2009-01-23	2010-07-29	Nsgene A/S	Expression de neuropeptides dans des cellules mammaliennes
EP2389435B1 (fr) *	2009-01-23	2015-11-04	NsGene A/S	Lignées cellulaires améliorées et leur utilisation pour la bio-deliverance de cellules encapsulées
WO2011153440A2 (fr)	2010-06-04	2011-12-08	Regents Of The University Of Minnesota	Système de mutagenèse par transposons et ses méthodes d'utilisation
ES2528892T3 (es)	2012-07-30	2015-02-13	Nbe-Therapeutics Llc	Identificación mediada por trasposición de proteínas de unión o funcionales específicas
US10041077B2 (en)	2014-04-09	2018-08-07	Dna2.0, Inc.	DNA vectors, transposons and transposases for eukaryotic genome modification
EP3215534B1 (fr)	2014-11-05	2020-04-15	Board of Regents, The University of Texas System	Récepteurs d'antigènes chimériques (car) pour cibler sélectivement des complexes protéiques
KR102615825B1 (ko)	2015-03-11	2023-12-21	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	전위효소 폴리펩타이드 및 이의 용도
LT3359671T (lt) *	2015-10-08	2021-12-10	Dna Twopointo Inc.	Dnr vektoriai, transpozonai ir transpozazės, skirti eukariotinio genomo modifikacijai
US11059879B2 (en)	2015-10-27	2021-07-13	Board Of Regents, The University Of Texas System	Chimeric antigen receptor molecules and uses thereof
CA3015642A1 (fr)	2016-02-26	2017-08-31	Poseida Therapeutics, Inc.	Systeme de transposon et procedes d'utilisation
EP3219803A1 (fr) *	2016-03-15	2017-09-20	Max-Delbrück-Centrum für Molekulare Medizin	Transposons « sleeping beauty » améliorés, kits et procédés de transposition
KR102497013B1 (ko)	2016-06-07	2023-02-20	맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친	Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포
JP7591342B2 (ja)	2016-06-08	2024-11-28	プレシゲン，インコーポレイテッド	Ｃｄ３３特異的キメラ抗原受容体
PL240585B1 (pl)	2016-07-18	2022-05-02	Helix Biopharma Corp	Chimeryczny receptor antygenowy (CAR), komórki immunologiczne zawierające CAR oraz kompozycja farmaceutyczna je zawierająca do leczenia nowotworów
DE102016214469A1 (de) *	2016-08-04	2018-02-08	Schaeffler Technologies AG & Co. KG	Drehmomentübertragungseinrichtung
WO2018112225A1 (fr) *	2016-12-14	2018-06-21	The J. David Gladstone Institutes	Procédés et compositions pour créer une banque de délétion et pour identifier une particule interférente défectueuse (dip)
US11278570B2 (en)	2016-12-16	2022-03-22	B-Mogen Biotechnologies, Inc.	Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3047313A1 (fr)	2016-12-16	2018-06-21	B-Mogen Biotechnologies, Inc.	Transfert ameliore de genes a mediation par transposon de la famille hat et compositions, systemes et methodes associes
EP4382913A3 (fr)	2017-01-10	2024-08-14	Precigen, Inc.	Modulation de l'expression de polypeptides par l'intermédiaire de nouveaux systèmes d'expression de commutateurs géniques
CN108728477B (zh) *	2017-04-24	2022-02-22	华东理工大学	一种高效的转座突变系统及构建方法
WO2018226897A1 (fr)	2017-06-07	2018-12-13	Intrexon Corporation	Expression de nouvelles étiquettes de cellules
US11441132B2 (en)	2017-08-21	2022-09-13	European Molecular Biology Laboratory	Mutated sleeping beauty transposase
KR102804751B1 (ko)	2017-08-23	2025-05-13	막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트	Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포
WO2019046815A1 (fr)	2017-08-31	2019-03-07	Poseida Therapeutics, Inc.	Système de transposon et procédés d'utilisation
AU2018329741B2 (en)	2017-09-08	2025-02-20	Poseida Therapeutics, Inc.	Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
KR20250136930A (ko)	2018-03-06	2025-09-16	프레시전 인코포레이티드	사람 파필로마바이러스 백신 및 이의 용도
JP2021514666A (ja)	2018-03-06	2021-06-17	プレシゲン，インコーポレイテッド	Ｂ型肝炎ワクチンおよびその使用
CN112189018A (zh)	2018-04-20	2021-01-05	汉诺威医学院	结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
EP3810764A2 (fr)	2018-06-21	2021-04-28	B-Mogen Biotechnologies, Inc.	Transfert amélioré de gènes médié par transposon de la famille hat et compositions, systèmes et méthodes associés
AU2019401282A1 (en)	2018-12-20	2021-07-15	Poseida Therapeutics, Inc.	Nanotransposon compositions and methods of use
CA3126773A1 (fr)	2019-02-13	2020-08-20	Probiogen Ag	Transposase ayant des proprietes de selection de site d'insertion ameliorees
ES2967879T3 (es)	2019-03-25	2024-05-06	Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft	Mejora de la actividad de los linfocitos T citolíticos mediante la inhibición de EBAG9
US11060098B2 (en) *	2019-04-08	2021-07-13	Dna Twopointo Inc.	Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias
EP3980458A1 (fr)	2019-06-05	2022-04-13	Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)	Récepteur d'auto-anticorps chimérique (caar) se liant à des auto-anticorps ciblant le système nerveux central dans une maladie auto-immune neurologique
AU2020298572A1 (en)	2019-07-02	2021-11-18	Fred Hutchinson Cancer Center	Recombinant Ad35 vectors and related gene therapy improvements
EP4025686A4 (fr)	2019-09-03	2023-09-13	Myeloid Therapeutics, Inc.	Méthodes et compositions d'intégration génomique
CN114761424B (zh)	2019-09-05	2025-09-19	波赛达治疗公司	同种异体细胞组合物和使用方法
CN115135672A (zh)	2019-12-20	2022-09-30	波赛达治疗公司	抗muc1组合物和使用方法
US20230104091A1 (en)	2020-03-04	2023-04-06	Poseida Therapeutics, Inc.	Compositions and methods for the treatment of metabolic liver disorders
WO2021183795A1 (fr)	2020-03-11	2021-09-16	Poseida Therapeutics, Inc.	Récepteurs stimulateurs chimériques et procédés d'utilisation dans l'activation et la différenciation de lymphocytes t
CN113584083A (zh) *	2020-04-30	2021-11-02	深圳市深研生物科技有限公司	用于逆转录病毒载体的生产细胞和包装细胞及其制备方法
CN117015600A (zh)	2020-07-17	2023-11-07	普罗拜奥根股份公司	高活性转座子和转座酶
KR102365768B1 (ko) *	2020-07-22	2022-02-18	인천대학교 산학협력단	개선된 슬리핑 뷰티 트랜스포존 시스템 및 이를 이용한 유전자 전위 방법
WO2022043315A1 (fr)	2020-08-24	2022-03-03	Charité - Universitätsmedizin Berlin	Construction de récepteur antigénique chimérique codant pour une molécule inhibitrice de point de contrôle et une cytokine immunostimulante et cellules exprimant car reconnaissant cd44v6
US20230321242A1 (en)	2020-08-24	2023-10-12	Charité - Universitätsmedizin Berlin	Chimeric antigen receptor (car)-expressing cells recognizing cea
WO2022087148A1 (fr)	2020-10-21	2022-04-28	Poseida Therapeutics, Inc.	Compositions et procédés d'administration d'acides nucléiques
EP4267602A1 (fr)	2020-12-22	2023-11-01	Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)	Récepteur d'auto-anticorps chimérique (caar) comprenant un autoantigène du récepteur nicotinique de l'acétylcholine
EP4019538A1 (fr)	2020-12-22	2022-06-29	Charité - Universitätsmedizin Berlin	Reprogrammation de cellules immunitaires par une intégration ciblée de transgènes de récepteur d'antigène chimérique déficient en zêta
TW202242117A (zh)	2020-12-30	2022-11-01	美商亞勞諾斯醫療公司	包含多順反子表現卡匣之重組載體及其使用方法
JP2024507846A (ja)	2021-02-23	2024-02-21	ポセイダセラピューティクス，インコーポレイティド	核酸の送達のための組成物及び方法
WO2022182797A1 (fr)	2021-02-23	2022-09-01	Poseida Therapeutics, Inc.	Cellules souches pluripotentes induites génétiquement modifiées et leurs procédés d'utilisation
US20240175047A1 (en)	2021-02-25	2024-05-30	Alaunos Therapeutics, Inc.	Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
WO2022187671A1 (fr)	2021-03-04	2022-09-09	Poseida Therapeutics, Inc.	Compositions et méthodes de traitement de l'hémophilie
JP2024518100A (ja)	2021-05-11	2024-04-24	マイエロイド・セラピューティクス，インコーポレーテッド	ゲノム組込みのための方法および組成物
EP4398915A1 (fr)	2021-09-09	2024-07-17	Iovance Biotherapeutics, Inc.	Procédés de production de produits til par inactivation de pd-1 avec talen
EP4148128A1 (fr) *	2021-09-09	2023-03-15	Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel	Polypeptides ayant une activité transpositionnelle
CA3233506A1 (fr)	2021-10-04	2023-04-13	Joseph S. LUCAS	Compositions de transposons et leurs procedes d'utilisation
AU2023210287A1 (en)	2022-01-21	2024-09-05	Poseida Therapeutics, Inc.	Compositions and methods for delivery of nucleic acids
JP2025504908A (ja)	2022-01-28	2025-02-19	アイオバンスバイオセラピューティクス，インコーポレイテッド	サイトカイン関連腫瘍浸潤リンパ球組成物及び方法
WO2023150562A1 (fr)	2022-02-01	2023-08-10	Alaunos Therapeutics, Inc.	Méthodes d'activation et d'expansion de lymphocytes t
US20250135039A1 (en)	2022-02-07	2025-05-01	Ensoma, Inc.	Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
EP4476351A1 (fr)	2022-02-09	2024-12-18	Horizon Discovery Limited	Polynucléotides avec marqueurs de sélection
US20250171809A1 (en)	2022-02-23	2025-05-29	Poseida Therapeutics, Inc.	Genetically modified cells and methods of use thereof
US20250216381A1 (en)	2022-03-21	2025-07-03	Alaunos Therapeutics, Inc.	Methods for Identifying Neoantigen-Reactive T Cell Receptors
US20240066127A1 (en)	2022-04-28	2024-02-29	Immatics US, Inc.	Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4514829A1 (fr)	2022-04-28	2025-03-05	Immatics US, Inc.	Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation
JP2025515604A (ja)	2022-04-28	2025-05-20	イマティクスユーエス，アイエヌシー．	ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
EP4568990A1 (fr)	2022-08-11	2025-06-18	Poseida Therapeutics, Inc.	Compositions chimériques de corécepteurs cd8-alpha et procédés d'utilisation
EP4353253A1 (fr)	2022-10-10	2024-04-17	Charité - Universitätsmedizin Berlin	Purification de lymphocytes t modifiés par tcr à l'aide de cellules car-nk spécifiques du tcr
EP4353821A1 (fr)	2022-10-10	2024-04-17	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	Mutant de transposase présentant une efficacité améliorée de transfert de gène
JP2025539816A (ja)	2022-11-21	2025-12-09	アイオバンスバイオセラピューティクス，インコーポレイテッド	腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
WO2024118836A1 (fr)	2022-11-30	2024-06-06	Iovance Biotherapeutics, Inc.	Procédés de production de lymphocytes infiltrant les tumeurs à étape rep raccourcie
EP4651943A1 (fr)	2023-01-20	2025-11-26	Poseida Therapeutics, Inc.	Composés lipidoïdes et compositions et utilisations associées
KR20250162510A (ko)	2023-01-20	2025-11-18	포세이다 테라퓨틱스, 인크.	리피도이드 화합물 및 관련 조성물 및 용도
WO2024178086A1 (fr)	2023-02-21	2024-08-29	Poseida Therapeutics, Inc.	Compositions polynucléotidiques de transposon piggybac d'aav et leurs procédés d'utilisation
AU2024224169A1 (en)	2023-02-21	2025-08-21	Poseida Therapeutics, Inc.	Compositions and methods for genome editing
IL322767A (en)	2023-02-21	2025-10-01	Poseida Therapeutics Inc	Genome editing vehicles and methods
WO2024197072A2 (fr)	2023-03-21	2024-09-26	Alaunos Therapeutics, Inc.	Identification de récepteurs de lymphocytes t réactifs à des néoantigènes
CN119053695B (zh) *	2023-03-27	2025-08-05	北京星辰集因科技有限责任公司	一种分离的转座酶及其用途
EP4501954A1 (fr)	2023-08-02	2025-02-05	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	Acide nucleique codant un co-recepteur de cd8 alpha beta, cellules et compositions pharmaceutiques le contenant
EP4506452A1 (fr)	2023-08-08	2025-02-12	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	Transposase ayant une biosécurité et une efficacité améliorées
EP4509522A1 (fr)	2023-08-16	2025-02-19	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	Récepteur de tgfbeta autocommutateur, acide nucléique le codant, cellules et compositions pharmaceutiques le comprenant
WO2025049925A2 (fr)	2023-09-01	2025-03-06	Poseida Therapeutics, Inc.	Composés lipidoïdes et compositions et utilisations associées
WO2025096649A1 (fr)	2023-11-01	2025-05-08	Immatics US, Inc.	Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation
WO2025101484A1 (fr)	2023-11-06	2025-05-15	Iovance Biotherapeutics, Inc.	Traitement de cancers endométriaux avec des thérapies lymphocytaires infiltrant les tumeurs
WO2025120230A1 (fr)	2023-12-07	2025-06-12	T-Curx Gmbh	Procédé de production de leucocytes exprimant des récepteurs d'antigènes chimériques
WO2025156492A1 (fr) *	2024-01-23	2025-07-31	星尘股份有限公司	Transposase et son utilisation
WO2025158420A1 (fr)	2024-01-25	2025-07-31	Nanocell Therapeutics Holdings B.V.	Méthodes et composition pour induire l'activation et l'expression d'adn dans des lymphocytes t
WO2025160432A1 (fr)	2024-01-26	2025-07-31	Poseida Therapeutics, Inc.	Méthodes et compositions pour améliorer la persistance in vivo et l'efficacité d'une thérapie cellulaire
WO2025171237A1 (fr)	2024-02-08	2025-08-14	Poseida Therapeutics, Inc.	Composés lipidoïdes et compositions et utilisations associées
WO2025169168A1 (fr)	2024-02-09	2025-08-14	Nanocell Therapeutics Holdings B.V.	Transfection extracorporelle de cellules effectrices immunitaires
WO2025176860A1 (fr)	2024-02-23	2025-08-28	Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts	Construction de récepteur antigénique chimérique double ciblant cea et epcam
WO2025221789A1 (fr)	2024-04-16	2025-10-23	Poseida Therapeutics, Inc.	Compositions et méthodes destinées à être utilisées dans des thérapies cellulaires car/tcr

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5620896A (en)	1992-03-23	1997-04-15	University Of Massachusetts Medical Center	DNA vaccines against rotavirus infections
KR20000076157A (ko)	1997-03-11	2000-12-26	리전츠 오브 더 유니버스티 오브 미네소타	세포의 디엔에이로 핵산을 도입하는 디엔에이-기초 전이인자 시스템
EP1034258A2 (fr)	1997-11-13	2000-09-13	The Regents Of The University Of Minnesota	Systeme de transposon a base d'adn permettant d'introduire un acide nucleique dans l'adn d'une cellule
AU4711000A (en)	1999-05-11	2000-11-21	Estuardo Aguilar-Cordova	Vector-mediated delivery of integrating transposon sequences
US6281298B1 (en) *	1999-08-20	2001-08-28	H. B. Fuller Licensing & Financing Inc.	Water-based pressure sensitive adhesives having enhanced characteristics
WO2001030965A2 (fr)	1999-10-28	2001-05-03	The Board Of Trustees Of The Leland Stanford Junior University	Methodes de transfert genique in vivo a l'aide d'un systeme de transposon «sleeping beauty»
DE10120829A1 (de)	2000-04-27	2001-12-20	Max Delbrueck Centrum	Sleeping Beauty, ein Transposonvektor mit breitem Wirtsbereich für die genetische Transformation bei Wirbeltieren
MXPA04003957A (es) *	2001-10-29	2004-06-22	Avery Dennison Corp	Peliculas de etiquetas y proceso de etiquetado.
US7985739B2 (en) *	2003-06-04	2011-07-26	The Board Of Trustees Of The Leland Stanford Junior University	Enhanced sleeping beauty transposon system and methods for using the same
US20060252140A1 (en) *	2005-04-29	2006-11-09	Yant Stephen R	Development of a transposon system for site-specific DNA integration in mammalian cells
US20130305398A1 (en) *	2012-02-16	2013-11-14	Marie Coffin	Genes and uses for plant enhacement
JP5726522B2 (ja) *	2007-07-04	2015-06-03	マックス−デルブリュック−ツェントルムフューアモレキュラーレメディツィン	トランスポゾンシステム−スリーピングビューティーのトランスポザーゼタンパク質の機能亢進性バリアント

2008
- 2008-06-30 JP JP2010513772A patent/JP5726522B2/ja active Active
- 2008-06-30 CA CA2692501A patent/CA2692501C/fr active Active
- 2008-06-30 EP EP08773780A patent/EP2160461B1/fr active Active
- 2008-06-30 AU AU2008271523A patent/AU2008271523B2/en active Active
- 2008-06-30 WO PCT/EP2008/005342 patent/WO2009003671A2/fr not_active Ceased
- 2008-06-30 US US12/667,527 patent/US9228180B2/en active Active
2015
- 2015-12-03 US US14/957,877 patent/US9840696B2/en active Active
2017
- 2017-11-03 US US15/803,643 patent/US11661588B2/en active Active
2023
- 2023-04-11 US US18/298,797 patent/US20230348867A1/en active Pending

Also Published As

Publication number	Publication date
CA2692501C (fr)	2017-10-10
US11661588B2 (en)	2023-05-30
WO2009003671A2 (fr)	2009-01-08
AU2008271523A1 (en)	2009-01-08
JP2010531650A (ja)	2010-09-30
EP2160461A2 (fr)	2010-03-10
US9228180B2 (en)	2016-01-05
US20110117072A1 (en)	2011-05-19
US20180135032A1 (en)	2018-05-17
JP5726522B2 (ja)	2015-06-03
US20230348867A1 (en)	2023-11-02
US20160264949A1 (en)	2016-09-15
US9840696B2 (en)	2017-12-12
AU2008271523B2 (en)	2015-09-10
EP2160461B1 (fr)	2012-08-08
WO2009003671A3 (fr)	2009-04-02

Publication	Publication Date	Title
US20230348867A1 (en)	2023-11-02	Transposon, gene transfer system and method of using the same
JP7365374B2 (ja)	2023-10-19	ヌクレアーゼ介在性遺伝子発現調節
RU2716420C2 (ru)	2020-03-11	Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
JP2018038410A (ja)	2018-03-15	リソソーム貯蔵疾患の処置のための方法および組成物
CA2932439A1 (fr)	2015-06-18	Systemes crispr-cas et methodes de modification de l'expression de produits geniques, informations structurales et enzymes cas modulaires inductibles
US20090217400A1 (en)	2009-08-27	Enzymes, cells and methods for site specific recombination at asymmetric sites
Voigt et al.	2008	Targeted gene insertion for molecular medicine
US20250002876A1 (en)	2025-01-02	Mobile elements and chimeric constructs thereof
WO2012074758A1 (fr)	2012-06-07	Transposases piggybac hyperactives
EP2025748A1 (fr)	2009-02-18	Variantes hyperactives de protéine transposase du système de transposon sleeping beauty
JP2024531217A (ja)	2024-08-29	遺伝子改変高忠実度ｏｍｎｉ－５０ヌクレアーゼバリアント
Meir et al.	2011	Transposon-based vector systems for gene therapy clinical trials: challenges and considerations
US7951927B2 (en)	2011-05-31	Reconstructed human mariner transposon capable of stable gene transfer into chromosomes in vertebrates
EP4353821A1 (fr)	2024-04-17	Mutant de transposase présentant une efficacité améliorée de transfert de gène
JP2024532784A (ja)	2024-09-10	新規なｏｍｎｉ－１１５、１２４、１２７、１４４～１４９、１５９、２１８、２３７、２４８、２５１～２５３及び２５９ｃｒｉｓｐｒヌクレアーゼ
JP2024540558A (ja)	2024-10-31	新規なｏｍｎｉｃｒｉｓｐｒヌクレアーゼ
WO2023081815A1 (fr)	2023-05-11	Fabrication de cellules souches
CN118660959A (zh)	2024-09-17	移动元件及其嵌合构建体
WO2023081816A2 (fr)	2023-05-11	Éléments mobiles transposables à sélection de site génomique améliorée
KR20250130659A (ko)	2025-09-02	Omni xl 1-22 crispr 뉴클레아제
KR20250152089A (ko)	2025-10-22	유전체 편집을 위한 조성물 및 방법

Legal Events

Date	Code	Title	Description
2013-07-31	EEER	Examination request	Effective date: 20130626